In the rare disease area, the NanoBriva™ platform allows for the design and production of  recombinant therapeutic proteins such as lysosomal enzymes developed within internal R&D programs.


Samabriva is developing its own therapeutic products and is keen to establish partnerships to develop new first-in-class products in the rare diseases area as part of a collaboration.

If you are interested


© 2020 created by Samabriva.